Schizophrenia is a severe neuropsychiatric disease associated with substantially higher mortality. Reduced life expectancy in schizophrenia relates to an increased prevalence of metabolic disturbance, and antipsychotic medication is a major contributor. Molecular mechanisms underlying adverse metabolic effects of antipsychotics are not fully understood; however, adipose tissue homeostasis deregulation appears to be a critical factor. We employed mass spectrometry-based untargeted proteomics to assess the effect of chronic olanzapine, risperidone, and haloperidol treatment in visceral adipose tissue of prenatally methylazoxymethanol (MAM) acetate exposed rats, a well-validated neurodevelopmental animal model of schizophrenia. Bioinformatics analysis of differentially expressed proteins was performed to highlight the pathways affected by MAM and the antipsychotics treatment. MAM model was associated with the deregulation of the TOR (target of rapamycin) signalling pathway. Notably, alterations in protein expression triggered by antipsychotics were observed only in schizophrenia-like MAM animals where we revealed hundreds of affected proteins according to our two-fold threshold, but not in control animals. Treatments with all antipsychotics in MAM rats resulted in the downregulation of mRNA processing and splicing, while drug-specific effects included among others upregulation of insulin resistance (olanzapine), upregulation of fatty acid metabolism (risperidone), and upregulation of nucleic acid metabolism (haloperidol). Our data indicate that deregulation of several energetic and metabolic pathways in adipose tissue is associated with APs administration and is prominent in MAM schizophrenia-like model but not in control animals.

• MeSH
• antipsychotika terapeutické užití   MeSH
• haloperidol farmakologie   terapeutické užití   MeSH
• krysa rodu rattus MeSH
• methylazoxymethanolacetát farmakologie   MeSH
• modely nemocí na zvířatech MeSH
• nitrobřišní tuk účinky léků   embryologie   metabolismus   MeSH
• olanzapin farmakologie   terapeutické užití   MeSH
• potkani Sprague-Dawley MeSH
• proteomika MeSH
• risperidon farmakologie   terapeutické užití   MeSH
• schizofrenie farmakoterapie   MeSH
• signální transdukce účinky léků   MeSH
• těhotenství MeSH
• TOR serin-threoninkinasy metabolismus   MeSH
• tuková tkáň účinky léků   metabolismus   MeSH
• zpožděný efekt prenatální expozice chemicky indukované   metabolismus   MeSH
• zvířata MeSH
• Check Tag
• krysa rodu rattus MeSH
• těhotenství MeSH
• ženské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH

In agreement with the neurodevelopmental hypothesis of schizophrenia, prenatal exposure of rats to the antimitotic agent methylazoxymethanol acetate (MAM) at gestational day 17 produced long-lasting behavioral alterations such as social withdrawal and cognitive impairment in the social interaction test and in the novel object recognition test, respectively. At the molecular level, an increased cannabinoid receptor type-1 (CB1) mRNA and protein expression, which might be due to reduction in DNA methylation at the gene promoter in the prefrontal cortex (PFC), coincided with deficits in the social interaction test and in the novel object recognition test in MAM rats. Both the schizophrenia-like phenotype and altered transcriptional regulation of CB1 receptors were reversed by peripubertal treatment (from PND 19 to PND 39) with the non-psychotropic phytocannabinoid cannabidiol (30 mg/kg/day), or, in part, by treatment with the cannabinoid CB1 receptor antagonist/inverse agonist AM251 (0.5 mg/kg/day), but not with haloperidol (0.6 mg/kg/day). These results suggest that early treatment with cannabidiol may prevent both the appearance of schizophrenia-like deficits as well as CB1 alterations in the PFC at adulthood, supporting that peripubertal cannabidiol treatment might be protective against MAM insult.

• MeSH
• endokanabinoidy metabolismus   MeSH
• ethanolaminy metabolismus   MeSH
• glyceridy metabolismus   MeSH
• hipokampus metabolismus   MeSH
• interpersonální vztahy MeSH
• kanabidiol farmakologie   MeSH
• krysa rodu rattus MeSH
• kyseliny arachidonové metabolismus   MeSH
• kyseliny olejové metabolismus   MeSH
• kyseliny palmitové metabolismus   MeSH
• messenger RNA metabolismus   MeSH
• methylazoxymethanolacetát farmakologie   MeSH
• modely nemocí na zvířatech MeSH
• piperidiny farmakologie   MeSH
• pohybová aktivita účinky léků   MeSH
• polynenasycené alkamidy metabolismus   MeSH
• prefrontální mozková kůra metabolismus   MeSH
• puberta MeSH
• pyrazoly farmakologie   MeSH
• receptor kanabinoidní CB1 metabolismus   MeSH
• rozpoznávání (psychologie) účinky léků   MeSH
• schizofrenie chemicky indukované   farmakoterapie   metabolismus   MeSH
• těhotenství MeSH
• zpožděný efekt prenatální expozice farmakoterapie   metabolismus   MeSH
• zvířata MeSH
• Check Tag
• krysa rodu rattus MeSH
• mužské pohlaví MeSH
• těhotenství MeSH
• ženské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH